Biological Therapies for Cancer: Technologies and Global Markets

  • Published: January 2015
  • |
  • Report Code: BIO048C

REPORT HIGHLIGHTS

The global market for biologic cancer treatment totaled about $51.2 billion in 2014 and is expected to reach $66.4 billion in 2019, registering a compound annual growth rate (CAGR) of 5.4% for the period 2014-2019.

This report provides:

  • An overview of the global markets and technologies for biological therapies for cancer
  • Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • Detailed analyses of products in the market, market structure and competitive environments, cancer markets in newly emerging therapeutics, and analysis of biosimilars and their impact on the market.
  • Details concerning the strengths, weaknesses, opportunities, and threats facing various cancer biotherapeutics already on the market.
  • A look at major issues involved in the research and development (R&D) of more effective cancer therapeutics, and new cancer therapeutics in development and in clinical trials.
  • Comprehensive profiles of major players in the cancer biotherapeutics field.

SAMPLE FIGURE
GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, 2008-2019
($ MILLIONS)
GLOBAL BIOLOGICAL CANCER TREATMENT MARKET BY SEGMENT, 2008-2019
To Contact us, click here  help


Source: BCC Research

Download Report Overview

REPORT SCOPE

SCOPE AND FORMAT

This report provides an update on BIO048B Biological Therapies for Cancer: Technologies and Global Markets. It reviews global markets for biologic therapeutics for cancer and forecasts trends for the use of biologics and cancer treatments through 2019. It discusses important biologics, market share by cancer type, products on the market, market share by company, statistical information for cancer types prevalent globally, with special emphasis on the U.S. market. It also includes current issues and trends affecting the industry, costs and factors influencing demand. The report covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products.

The market and sales data for various years gives strong support for the research and development (R&D) program and the move toward biologic treatment for cancer, as well as within biologic toward human monoclonal antibodies, vaccines and interferons. The biologic drug classes discussed in this report with special focus on cancer treatment are:

  • Monoclonal antibodies.
  • Vaccines.
  • Erythropoietin.
  • Colony stimulating factors. 
  • Interleukins and interferons.

The following approaches to cancer therapeutics are excluded in the report:

  • Chemotherapy.
  • Alkylating agents.
  • Antimetabolites.
  • Cytotoxic agents.
  • Plant derivatives and hormone therapy corticosteroids. 
  • Hormone antagonists/antagonists aromatase inhibitors. 
  • Radiation therapy. 
  • Adjunctive therapy.

Biological therapies for treatment of other diseases will not be addressed in this report.

The report also covers biological products in development, biological products in clinical trials, and currently marketed and late-stage development biologic cancer products, including:

  • Treatment trends and sales patterns across major cancer indications for Japan, Europe E.U.5 nations (i.e., France, Germany, Italy, Spain, the U.K.), the U.S. and the rest of the world (ROW).
  • Market performance of major pharmaceutical companies. 
  • Forecast sales of leading products across major indications to 2019.
  • Biosimilars and their impact on currently marketed cancer biotherapeutics.

ANALYST’S CREDENTIALS

Usha Nagavarapu is an experienced pharmaceutical professional with business development experience. She has more than 10 years of pre-clinical, alliance management, discovery and technology development, and marketing experience. Her primary focus areas include oncology and cardiovascular diseases, along with expertise in molecular and cell biology and complex cell-based biological assays, ranging from drug discovery, in vitro and in vivo screening, in vivo model development and pharmacokinetics. She also has experience working with early start-up companies.


Download Report Overview

REPORT TOC

Pricing on the website is provided for single users and 2-5 users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at (+1)781-489-7301 or send an email to information@bccresearch.com
  Title/Chapter Name Pages Price
Biological Therapies for Cancer: Technologies and Global Markets 346 $6650
Chapter- 1: INTRODUCTION - Complimentary 3 $0
  Show Details
Chapter- 2: SUMMARY 2 $250
  Show Details
Chapter- 3: BIOLOGICAL TREATMENTS FOR CANCER 6 $173
  Show Details
Chapter- 4: CANCER DESCRIPTIONS 92 $2652
  Show Details
Chapter- 5: PRODUCT SEGMENTS AND TECHNOLOGY 44 $1268
  Show Details
Chapter- 6: MARKET DYNAMICS AND OVERVIEW 33 $951
  Show Details
Chapter- 7: PRODUCTS IN DEVELOPMENT 33 $951
  Show Details
Chapter- 8: ONCOLOGY DRUG MARKET 23 $663
  Show Details
Chapter- 9: GLOBAL CANCER STATISTICS 40 $1153
  Show Details
Chapter- 10: BIOLOGIC CANCER MARKET ISSUES AND TRENDS 48 $1384
  Show Details
Chapter- 11: COMPANY PROFILES 20 $577
  Show Details
Chapter- 12: REFERENCES 2 $58
  Show Details
 
  List of Tables
  List of Figures
download report overview
Select License type:
buy now

Preferred Pricing available for:

  • Startup or Small Business (Revenue <$1M)
  • Academic Institute
  • Government Agency
  • Nonprofit Organization
Get Started
Want to find out more
about this report?
request more info
Get Notified
on all the latest research reports
Subscribe